Aligos Advances HBV Pipeline with Key Study Milestones and Commercial Hire
Event summary
- Completed enrollment of 60 HBeAg- participants in Phase 2 B-SUPREME study of pevifoscorvir sodium in January 2026.
- ALG-170675 advanced into IND-enabling studies with Amoytop funding development in China.
- ALG-055009 showed synergistic weight loss in combination with semaglutide and tirzepatide in DIO mice.
- Appointed James Hassard as Executive Vice President, Chief Commercial Officer.
- Cash position grew to $77.8M as of December 31, 2025, expected to fund operations into Q3 2026.
The big picture
Aligos is advancing its HBV pipeline with strategic milestones in pevifoscorvir sodium's Phase 2 study and ALG-170675's IND-enabling work. The appointment of a Chief Commercial Officer signals preparation for future product launches, while the company's improved cash position provides runway into 2026. The biotech's focus on combination therapies for obesity and MASH positions it in a competitive but growing market.
What we're watching
- Clinical Momentum
- Whether interim analyses in 2026 for pevifoscorvir sodium will validate its multi-mechanism approach to HBV.
- Commercial Strategy
- How James Hassard's appointment will shape Aligos' global commercial capabilities ahead of potential product launches.
- Funding Strategy
- The pace at which Aligos secures additional funding for ALG-055009 development, including potential out-licensing.
Related topics